With the emergence and long-term Impact of COVID-19, Global Allergy Immunotherapy Market to reach USD 4.12 billion by 2030
Bizwit Research & Consulting LLP’s recent analysis on the Global Allergy Immunotherapy Market points towards a potential rise to USD 4.12 billion by 2030. Allergy immunotherapy is a medical treatment for allergies. It is a long-term therapy that aims to desensitize a person’s immune system to specific allergens, such as pollen, dust mites, pet dander, or certain insect venoms.
The goal of allergy immunotherapy is to modify the immune response to allergens, leading to a reduction in allergy symptoms. It can be effective in treating allergic rhinitis (hay fever), allergic asthma, and insect venom allergies. Allergy shots can provide long-term relief, even after the treatment is completed. The Allergy Immunotherapy market is expanding because of factors such as the increasing burden of various types of allergies and rising demand for personalized medicine.
Geographically, the global Allergy Immunotherapy market has been segmented into North America, Europe, Asia Pacific (APAC), Latin America, and Middle East and Africa (MEA). North America dominated the market in 2022 with largest market share owing to the dominance of key market players, rising prevalence of allergy disorders, rising number of product launch activities in the region. Whereas, Asia Pacific region is projected to have fastest growth owing to factors such as rising disease prevalence, rising expansion by key market players in the region as well as rising number of awareness programs in the region.
The global Allergy Immunotherapy market is highly competitive owing to the presence of several key players such as Torii Pharmaceutical Co., Ltd, ALK-Abello A/S Allergy Therapeutics, Biomay AG Allovate, LLC, HAL Allergy Group, Jubliant Pharma (Hollister Allergy), Leti Pharma Merck KGaA (Allergopharma), Stallergenes Greer and others.
For further analysis on this or to request a sample copy of this report, please click the link mentioned below:
Key findings of the study suggest:
- Global Allergy Immunotherapy Market is anticipated to grow with a healthy growth rate of more than 9.0% over the forecast period 2023-2030.
- In the Treatment Type segment, Subcutaneous Immunotherapy (SCIT) emerged out as the leading market segment in 2022.
- North America is anticipated to drive regional growth owing to rising prevalence of allergy disorders in the region.
- Asia Pacific is expected to grow at higher rate owing to rising number of awareness programs in the region
Bizwit Research & Consulting has considered following segments for the study:
By Treatment Type:
- Subcutaneous Immunotherapy (SCIT)
- Sublingual Immunotherapy (SLIT)
By Allergy Type:
- Allergic rhinitis
- Allergic asthma
- Others
By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Regional Outlook
- North America
- US
- Canada
- Europe
- UK
- Germany
- France
- Spain
- Italy
- ROE
- Asia Pacific
- China
- India
- Japan
- Korea
- Australia
- RoAPAC
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
To get a sample of this report or to purchase a copy of the study, you can directly contact us at: sales@bizwitresearch.com
About Us
Bizwit Research & Consulting LLP is a global provider of business intelligence & consulting services. The company has a strong primary base of key industry leaders along with the chain of industry analysts to analyze the market trends and its future impact in order to estimates and forecast different business segments and markets. Bizwit incorporate big data, expert analysis, and huge industry database to deliver client focused business consulting reports. Our analysts perform unbiased measurement and assessment of market opportunities to comprehend detailed market forecast. Our team of key opinion leaders evaluates the market size, growth prospects, end-use, applications, value & supply chain and top vendors in the industry to help the clients to take conversant business decisions without any vague assumptions.
Contact US
Global Business Development
Phone: +1 209 498-3066
Email: Sales@bizwitresearch.com
Website: www.bizwitresearch.com
